Browsing by Author Millar, Jeremy

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2017Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialKing, Madeleine; Stockler, Martin; Turner, Sandra Lynne; Woo, Henry; Ames, Alice; Bowe, Steven J.; D'Este, Catherine; Duchesne, Gillian; Frydenberg, Mark; Loblaw, Andrew; Malone, Shawn; Millar, Jeremy; Tai, Keen Hun; Psychology; NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; SAHCS: SurgeryHealth-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, The Lancet Oncology, vol.18, 9, 2017,pp 1192-1201
2015Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy RegistryPatel, Manish; Bolton, Damien; Davidson, Adee-Jonathan; Giles, Graham; Millar, Jeremy; Papa, Nathan P; Pedersen, John; Syme, Rodney; Ta, Anthony D.; Western Clinical School: SurgeryPredictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry, BJU International, vol.116, Suppl3, 2015,pp 66-72
2016Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialKing, Madeleine; Stockler, Martin; Woo, Henry; Bassett, Julie; Bowe, Steven; D'Este, Catherine; Duchesne, Gillian; et al, .; Frydenberg, M; Ledwich, Leo; Loblaw, Andrew; Malone, Shawn; Millar, Jeremy; Milne, Roger; Psychology; NH&MRC Clinical Trials Centre; SAHCS: SurgeryTiming of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncology, vol.17, 6, 2016,pp 727-737